Lipanthyl Micronisé

Fenofibrate, the active ingredient in Lipanthyl Micronisé, is a fibric acid derivative presented as a micronised oral tablet for oral use. It is employed to lower elevated triglyceride levels and to improve lipid profiles in patients with dyslipidaemia, helping reduce cardiovascular risk and is indicated for the management of hypertriglyceridaemia and mixed dyslipidaemia.

GNH USA supplies Lipanthyl Micronisé as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams worldwide across multiple continents.

Lipanthyl Micronisé (fenofibrate) acts on lipid metabolism pathways to modify triglyceride‑rich lipoproteins and is used in several dyslipidaemia conditions, including primary and secondary forms.

Hypertriglyceridaemia: lowers serum triglyceride concentrations, reducing the risk of pancreatitis and supporting overall lipid balance. Mixed dyslipidaemia: decreases triglycerides and modestly reduces LDL‑cholesterol while raising HDL‑cholesterol, improving the atherogenic profile. Secondary prevention of cardiovascular disease associated with dyslipidaemia: contributes to risk reduction when combined with statin therapy and lifestyle measures.

Fenofibrate may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia - Headache: mild to moderate intensity - Dizziness: transient episodes - Elevated liver enzymes: mild increases in ALT or AST

Serious or Rare Side Effects: - Rhabdomyolysis: muscle breakdown with potential renal failure - Severe liver injury: hepatitis or hepatic failure - Allergic reactions: rash, pruritus or angioedema

When prescribing fenofibrate, clinicians should consider several precautionary measures to ensure patient safety. - Monitor liver function: obtain baseline transaminases and repeat periodically. - Assess renal function: adjust use in patients with severe impairment. - Review concomitant medications: avoid or monitor use with statins and gemfibrozil. - Avoid in active gallbladder disease: fenofibrate can promote gallstone formation. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Store at ambient temperature: keep in original container, protect from moisture and light.

Fenofibrate can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Gemfibrozil: combined use markedly increases risk of myopathy and rhabdomyolysis. - High‑dose statins (e.g., simvastatin >40 mg): additive risk of muscle toxicity. - Cyclosporine: may raise fenofibrate plasma concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: fenofibrate may potentiate anticoagulant effect, requiring INR monitoring. - Thiazide diuretics: can cause modest increases in serum creatinine. - Oral contraceptives: may attenuate triglyceride‑lowering response.